iVexSol, a rapidly growing lentiviral vector (LVV) manufacturing company, announced the closure of a $13 million Series A funding round. A total of $15.2 million has been raised to date from current investors Casdin Capital, LLC , and BioLife Solutions (NASDAQ:BLFS) and a third undisclosed lead investor. Funds will be used to establish a cGMP manufacturing facility in Lexington, MA for stable LVV producer cell line master banks and commercial-grade LVV.
iVexSol was one of three Worcester-based companies to be awarded a Seed Fund investment by the MLSC. The Seed Fund’s mission is to advance innovative and promising life science companies in targeted geographies (Amherst, Beverly, Lowell, Mansfield, North Adams, Springfield, Pittsfield, and Worcester) by working with partners to leverage resources and promote economic development.
